NASDAQ:SPTX Seaport Therapeutics (SPTX) Stock Price, News & Analysis $24.83 +0.75 (+3.11%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Seaport Therapeutics Stock (NASDAQ:SPTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seaport Therapeutics alerts:Sign Up Key Stats Today's Range$24.25▼$25.4250-Day Range$17.10▼$24.8352-Week Range$14.85▼$26.47Volume85,785 shsAverage Volume117,407 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$38.40Consensus RatingHold Company Overview Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON. Read More Seaport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreSPTX MarketRank™: Seaport Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 376th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSeaport Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialSeaport Therapeutics has a consensus price target of $38.40, representing about 54.7% upside from its current price of $24.83.Amount of Analyst CoverageSeaport Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Seaport Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Seaport Therapeutics are expected to grow in the coming year, from ($4.60) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seaport Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seaport Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.63% of the float of Seaport Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeaport Therapeutics has a short interest ratio ("days to cover") of 25.13, which indicates bearish sentiment.Change versus previous monthShort interest in Seaport Therapeutics has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeaport Therapeutics does not currently pay a dividend.Dividend GrowthSeaport Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentSeaport Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Seaport Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for SPTX on MarketBeat in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $235,820.00 in company stock, which represents 0.0177% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Seaport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $235,820.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsSeaport Therapeutics has minimal institutional ownership at this time.Read more about Seaport Therapeutics' insider trading history. Receive SPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seaport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPTX Stock News HeadlinesHC Wainwright Reaffirms "Buy" Rating for Seaport Therapeutics (NASDAQ:SPTX)August 22 at 1:54 AM | americanbankingnews.comSeaport Therapeutics (NASDAQ:SPTX) Sets New 1-Year High - Still a Buy?August 18, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 25 at 1:00 AM | Profits Run (Ad)Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of ValidationAugust 11, 2026 | seekingalpha.comSeaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressAugust 3, 2026 | businesswire.comSeaport Therapeutics (SPTX) Stock Forecast & Price TargetJuly 19, 2026 | investing.comSeaport Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SPTXJuly 17, 2026 | benzinga.comSeaport Therapeutics, Inc. (SPTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comSee More Headlines SPTX Stock Analysis - Frequently Asked Questions How have SPTX shares performed this year? Seaport Therapeutics' stock was trading at $19.84 on April 30, 2026. Since then, SPTX shares have increased by 25.2% and is now trading at $24.83. How were Seaport Therapeutics' earnings last quarter? Seaport Therapeutics, Inc. (NASDAQ:SPTX) issued its earnings results on Monday, August, 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $1.07. When did Seaport Therapeutics IPO? Seaport Therapeutics (SPTX) raised $241 million in an initial public offering on Friday, May 1st 2026. The company issued 14,160,000 shares at a price of $16.00-$18.00 per share. When does the company's lock-up period expire? Seaport Therapeutics's lock-up period expires on Wednesday, October 28th. Seaport Therapeutics had issued 14,160,000 shares in its IPO on May 1st. The total size of the offering was $254,880,000 based on an initial share price of $18.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are Seaport Therapeutics' major shareholders? Top institutional shareholders of Seaport Therapeutics include TRV GP VI LLC (3.85%), Braidwell LP (0.93%) and Alyeska Investment Group L.P. (0.14%). Insiders that own company stock include Arch Venture Partners Xii, Llc and Robert J Hombach. View institutional ownership trends. How do I buy shares of Seaport Therapeutics? Shares of SPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/03/2026Today8/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPTX CIK2042347 Webwww.seaporttx.com Phone617-807-4062FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Seaport Therapeutics$38.40 High Price Target$50.00 Low Price Target$30.00 Potential Upside/Downside+54.7%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio18.00 Quick Ratio18.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.89 per share Price / Book3.15Miscellaneous Outstanding Shares53,530,000Free FloatN/AMarket Cap$1.33 billion OptionableN/A BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SPTX) was last updated on 8/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seaport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seaport Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
